Hua Medicine (2552) AI Stock Analysis

• Market Cap: HK$3.16B
• Dividend Yield: N/A
• Average Volume (3M): 6.34M
• Price to Earnings (P/E): 0.5
• Beta (1Y): 1.23
• Revenue Growth: 238.71%
• EPS Growth: N/A
• Country: HK
• Employees: 168
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.30
• Shares Outstanding: 1,056,605,000
• 10 Day Avg. Volume: 6,422,209
• 30 Day Avg. Volume: 6,335,350
• PEG Ratio: -0.39
• Price to Book (P/B): -9.93
• Price to Sales (P/S): 5.26
• P/FCF Ratio: -3.19
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.02
• Revenue Forecast (FY): HK$974.21M

• Rating: 46 Neutral
• Price Target: HK$2.50 ▼(-24.01% Downside)
• Action: Reiterated Date: 02/03/26
• Date: Action: Reiterated 02/03/26

The score is primarily held back by weak financial quality (negative operating/free cash flow and poor core profitability) and bearish technicals (below major moving averages with negative MACD). A low P/E provides some valuation support, but it is tempered by the company’s profitability and cash burn issues.

Positive Factors

Revenue Growth

Sustained 18.32% TTM revenue growth indicates expanding commercial traction for its diabetes therapies and strengthens the recurring sales base. Over the next 2–6 months this supports reinvestment in R&D and commercialization, validating product-market fit.

Manageable Leverage

A debt-to-equity of 0.26 implies limited leverage, giving the company financial flexibility to fund operations, negotiate partnerships, or raise modest debt without severe solvency risk. This supports strategic moves while addressing cash burn over the medium term.

Commercialization and Partner Revenue Mix

Revenue sources from product sales, collaborations, milestones and licensing create diversified cash inflows. Structural mix reduces dependence on single channels, provides non-dilutive milestone or royalty upside and supports longer-term funding of pipeline development.

Negative Factors

Negative Operating and Free Cash Flow

Ongoing negative operating and free cash flow indicate persistent cash burn that will likely require external financing or partnerships. Over 2–6 months this constrains discretionary spending, risks dilution or higher leverage, and limits independent scaling of commercialization.

Weak Core Profitability

Negative operating margins show the core business is not yet profitable and a one-time gain masks true performance. Structurally weak margins reduce ability to self-fund R&D and commercialization, forcing reliance on external capital absent meaningful margin improvement.

Low Return on Equity

Low ROE reflects limited effectiveness in converting equity into profits, signaling operational or capital allocation inefficiencies. Over the medium term this can dampen investor confidence, raise the cost of new equity financing and pressure strategic flexibility.

Hua Medicine Business Overview & Revenue Model

Company Description

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

How the Company Makes Money

Hua Medicine generates revenue primarily through the commercialization of its pharmaceutical products, particularly its lead candidate for type 2 diabetes. The company may also engage in collaborations and partnerships with other pharmaceutical companies, research institutions, and healthcare organizations to co-develop products or share research costs. These partnerships can provide additional funding through upfront payments, milestone payments based on development progress, and royalties on future sales. Furthermore, Hua Medicine may receive revenue from licensing agreements, where it licenses its technology or products to other firms for further development and marketing. Additionally, the company may explore public and private investments to fund its ongoing research and development efforts, contributing to its overall financial health.

Hua Medicine Financial Statement Overview

Summary

Revenue growth is strong (18.32% TTM), but core profitability is weak with negative EBIT/EBITDA margins and operating/free cash flow remains negative. Leverage is manageable (debt-to-equity 0.26), yet low ROE and ongoing cash burn limit overall financial strength.

Income Statement

Hua Medicine shows a strong revenue growth rate of 18.32% TTM, indicating positive sales momentum. However, the company faces significant profitability challenges with negative EBIT and EBITDA margins, suggesting operational inefficiencies. The net profit margin is positive due to a one-time gain, but core profitability remains weak.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.26 TTM, indicating manageable leverage. However, the return on equity is low, suggesting limited returns for shareholders. The equity ratio is healthy, but the company needs to improve profitability to enhance financial stability.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating cash burn issues. The free cash flow to net income ratio is nearly 1, showing alignment between cash flow and accounting profits. However, negative free cash flow growth highlights ongoing cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	370.66M	255.89M	76.61M	17.60M	0.00	8.66M
Gross Profit	194.78M	124.72M	37.37M	7.69M	0.00	8.66M
EBITDA	-216.67M	-345.36M	-167.09M	-168.06M	-309.69M	-347.43M
Net Income	1.08B	-250.14M	-211.23M	-203.77M	-330.95M	-396.43M
Balance Sheet
Total Assets	1.42B	1.53B	1.73B	1.12B	903.55M	1.20B
Cash, Cash Equivalents and Short-Term Investments	1.02B	1.14B	1.46B	490.63M	675.24M	1.03B
Total Debt	271.05M	300.18M	167.75M	97.58M	71.53M	80.72M
Total Liabilities	360.82M	1.66B	1.62B	841.92M	453.22M	466.03M
Stockholders Equity	1.06B	-135.47M	101.15M	279.58M	450.33M	732.50M
Cash Flow
Free Cash Flow	-274.64M	-421.83M	879.52M	-257.58M	-339.87M	-46.60M
Operating Cash Flow	-275.61M	-417.97M	889.37M	-230.11M	-272.98M	-20.91M
Investing Cash Flow	6.93M	10.04M	8.08M	-4.75M	-68.22M	-14.09M
Financing Cash Flow	-48.04M	83.72M	69.07M	21.48M	-6.13M	-7.26M

Hua Medicine Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2552, the sentiment is Positive. The current price of 3.29 is above the 20-day moving average (MA) of 3.09, above the 50-day MA of 3.11, and below the 200-day MA of 3.38, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.87 is Neutral, neither overbought nor oversold. The STOCH value of 74.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2552.

Hua Medicine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2877	73 Outperform	HK$6.96B	2.21	10.84%	5.80%	-20.64%	-25.39%
2348	72 Outperform	HK$1.73B	4.06	5.33%	5.16%	2.89%	-68.83%
2633	69 Neutral	HK$2.39B	5.13	12.97%	15.40%	-1.88%	17.57%
1061	64 Neutral	HK$2.28B	3.83	14.24%	3.37%	7.16%	19.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2552	46 Neutral	HK$3.16B	0.54	206.86%	―	238.71%	―

Hua Medicine Corporate Events

Hua Medicine Advances Diabetes Treatment with New Phase Ib Trial

Hua Medicine has announced the successful dosing of the first patient in a U.S.-based Phase Ib trial for their second-generation glucokinase activator, HMS1005. This trial aims to assess the safety and efficacy of the drug, which is designed for once-daily administration to improve GLP-1 secretion in Type 2 diabetes patients. The company plans to seek global partners for further development upon successful completion of this trial, potentially enhancing its market position in diabetes treatment.

The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.

Hua Medicine Grants Share Options to Drive Growth and Commitment

Hua Medicine announced the grant of 20 million share options to three executive directors and 71 employees under its share option scheme. This initiative aims to reward outstanding performance and align employee interests with company growth, with vesting contingent on achieving specific revenue targets over the next three years, reinforcing long-term commitment without a clawback mechanism.

The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.

Hua Medicine Announces Changes to Remuneration Committee

Hua Medicine has announced a change in the composition of its Remuneration Committee, appointing Mr. Yiu Leung Andy Cheung as a new member effective November 27, 2025. This appointment reflects the company’s ongoing efforts to strengthen its governance structure, potentially impacting its operational efficiency and stakeholder confidence.

The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.

Hua Medicine Updates Board of Directors and Committee Roles

Hua Medicine has announced an updated list of its board of directors effective November 27, 2025. The announcement details the roles and committee memberships of each director, highlighting the strategic leadership structure within the company. This update may influence the company’s governance and strategic direction, impacting stakeholders and potentially enhancing its position in the pharmaceutical industry.

The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.